Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spleen Irradiation with Chemotherapy in Metastatic Pancreatic Cancer
NCT05363007Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- May 2022
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: 12-week Progression-Free Survival. Status: unknown.
Beyond the preview
Go deeper on NCT05363007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363007.